Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iressa plus Anastrozole in Relapsed Ovarian Cancer
NCT00181688Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Oct 2003
- Primary completion
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in ovarian cancer, primary peritoneal carcinoma (PPC) and fallopian tube carcinoma (PFTC), sponsored by Massachusetts General Hospital. Primary endpoint: Median Time to Termination of Treatment. Started Oct 2003; status: completed.
02
Drugs
03
Conditions
ovarian cancerprimary peritoneal carcinoma (PPC)fallopian tube carcinoma (PFTC)
Beyond the preview
Go deeper on NCT00181688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00181688.